STAT3 Cancer Research Results

STAT3, Signal transducer and activator of transcription 3: Click to Expand ⟱
Source:
Type: Oncogene
Stat3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a crucial role in various cellular processes, including cell growth, survival, differentiation, and immune response.
Stat3 is frequently found to be constitutively activated in many types of cancers, including breast, prostate, lung, and head and neck cancers. (associated with poor prognosis and reduced survival.)

-STAT3 is typically activated by cytokines (such as IL-6) and growth factors binding to their respective receptors.
-Activated STAT3 upregulates the expression of genes that promote cell cycle progression (e.g., cyclin D1) and anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL).
Scientific Papers found: Click to Expand⟱
7730- isoFl,    Anticancer Potential of Isoflavones: A Narrative Overview of Mechanistic Insights and Experimental Evidence from the Past Ten Years
- Review, Var, NA
Apoptosis↑, ROS↓, TumCCA↓, TumCMig↓, TumCI↓, MMP↓, angioG↓, ChemoSen↑, p‑Akt↓, p‑mTOR↓, cl‑PARP↑, cycA1/CCNA1↓, CycB/CCNB1↓, STAT3↓,
7858- isoO,    Isoorientin inhibits epithelial-to-mesenchymal properties and cancer stem-cell-like features in oral squamous cell carcinoma by blocking Wnt/β-catenin/STAT3 axis
- in-vitro, Oral, SCC25
CSCs↓, EMT↓, JAK↓, STAT3↓, Wnt↓, β-catenin/ZEB1↓, p‑GSK‐3β↓, TCF7/TCF1↓, LEF1↓, ChemoSen↑,
7856- isoO,    Isoorientin induces the apoptosis and cell cycle arrest of A549 human lung cancer cells via the ROS‑regulated MAPK, STAT3 and NF‑κB signaling pathways
- in-vitro, Lung, A549
Bacteria↓, Inflam↓, TumCD↑, selectivity↑, Apoptosis↑, MMP↓, BAX↑, cl‑Casp3↑, PARP↓, Bcl-2↓, TumCCA↑, CycB/CCNB1↓, CDK1↓, CDK2↓, NA↑, p27/CDKN1B↑, ROS↑, eff↓, p‑p38↑, p‑JNK↑, ERK↓, STAT3↓, NF-kB↓,
7873- isoO,    Isoorientin attenuates doxorubicin-induced cardiac injury via the activation of MAPK, Akt, and Caspase-dependent signaling pathways
- in-vitro, Liver, HepG2 - in-vitro, CRC, HT-29 - in-vitro, Lung, A549
ChemoSen↑, TumCP↓, chemoP↑, *ROS↓, *mtDam↓, *Apoptosis↓, *cardioP↑, *NRF2↑, *TGF-β↑, *p‑JNK↓, *p‑p38↓, *MAPK↝, *Akt↝, *STAT3↝,
7837- ISQ,    Isoquercitrin Delays Denervated Soleus Muscle Atrophy by Inhibiting Oxidative Stress and Inflammation
- in-vivo, Nor, NA
*Dose↝, *autophagy↓, *ATG7↓, *BNIP3↓, *LC3B↓, *PINK1↓, *ROS↓, *SOD1↑, *SOD2↑, *NRF2↑, *NQO1↑, *HO-1↑, *NOX2↓, *NOX4↓, *DUOX1↓, *IL1β↓, *IL6↓, *TNF-α↓, *JAK↓, *STAT3↓, *Inflam↓,
8038- IVM,    Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
- in-vitro, PC, NA
*AntiP↑, AntiTum↑, ChemoSen↑, TumCP↓, TumCCA↑, cycD1/CCND1↓, mTOR↓, STAT3↑, Apoptosis↑, mtDam↑, ROS↑, MMP↓, OCR↓, MitoP↓,
8040- IVM,    Ivermectin, a potential anticancer drug derived from an antiparasitic drug
- Review, Var, NA
Akt↓, mTOR↓, TumAuto↑, TumCP↓, TumCCA↑, Wnt↓, YAP/TEAD↓, MMP↓, mitResp↓, ATP↓, eff↓, eff↑, ROS↑, ChemoSen↑, PAK1↓, MAPK↓, EMT↓, Beclin-1/ATG6↑, ATG5↑, CSCs↓, STAT3↝, P-gp/ABCB1↓, MDR1↓, HSP27↓, Chl↑, TFE3↑,
1168- IVM,  SRF,    Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
- in-vitro, HCC, NA
TumMeta↓, mTOR↓, EMT↓, CSCsMark↓, STAT3↓,
1070- IVM,    Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation
- vitro+vivo, GBM, NA
TumCG↓, LC3II↑, p62↓, ATP↓, Pyruv↓, GlucoseCon↑, HK2↓, PFK1↓, GLUT4↓, Glycolysis↓, JAK2↓, p‑STAT3↓, p‑STAT5↓,
8002- JG,    Identification and Biological Evaluation of Juglone-Derived STAT3 Inhibitors against Colorectal Cancer
- in-vitro, PC, NA - in-vitro, CRC, NA
eff↑, STAT3↓, TumCP↓, selectivity↑,
7966- JG,    Discovery of Juglone Derivatives as Novel STAT3 Inhibitors with Potent Suppression of Cancer Cell Stemness against Breast Cancer
- in-vitro, BC, NA
STAT3↓, CSCs↓,
8085- KAE,    Effects and Mechanisms of Kaempferol in the Management of Cancers through Modulation of Inflammation and Signal Transduction Pathways
- Review, Var, NA
Apoptosis↑, TumCCA↑, angioG↓, PI3K↓, Akt↓, STAT3↓, AP-1↓, NRF2↓, BioAv↑, Inflam↓, NF-kB↓, TNF-α↓, VEGF↓, BAX↑, Casp↑, Bcl-2↓, P53↑, PTEN↑, hTERT/TERT↓, NRF2↓, ROS↑, DR5↑, ERK↑, CHOP/DDIT3↑, DR4↑, JNK↑, Ki-67↓, ChemoSen↑,
8095- KAE,    Kaempferol: A Key Emphasis to Its Anticancer Potential
- Review, Var, NA
*AntiBio↑, *Inflam↓, *AntiTum↓, *antiOx↑, *cardioP↑, *neuroP↑, *AntiDiabetic↑, Risk↓, TumCCA↑, EMT↓, PI3K↓, Akt↓, MMP2↓, Casp3↑, Casp7↑, Casp9↑, PARP↑, *ROS↓, angioG↓, *BioAv↑, BioAv↑, selectivity↑, GLUT1↓, MCT1↓, ROS↓, ROS↑, Trx↓, Cyt‑c↑, MMP↓, miR-21↓, SOCS-3↓, STAT3↓, CDK1↓, CycB/CCNB1↑, HIF-1↓, JAK1↑, PTEN↑,
8097- KAE,    The Phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells
- in-vitro, CRC, LS174T
ChemoSen↑, tumCV↓, Apoptosis↑, TumCCA↑, ROS↓, Casp3↑, Casp9↑, cl‑PARP↑, p‑STAT3↓, Akt↓, FOXO3↓, NF-kB↓, VEGF↓, TS↓, TK1↓,
8099- KAE,  LT,  CHr,    Kaempherol and Luteolin Decrease Claudin-2 Expression Mediated by Inhibition of STAT3 in Lung Adenocarcinoma A549 Cells
- in-vitro, Lung, A549
CLDN2↓, TumCP↓, STAT3↓,
8063- KAE,    Kaempferol exerts anti-proliferative effects on human ovarian cancer cells by inducing apoptosis, G0/G1 cell cycle arrest and modulation of MEK/ERK and STAT3 pathways
- in-vitro, Ovarian, NA
Dose↓, selectivity↑, Casp3↑, Casp8↑, Casp9↑, BAX↑, TumCCA↑, MEK↓, ERK↓, STAT3↓,
8055- KAE,    Molecular Mechanisms of the Anticancer Activity of the Flavonoid Kaempferol: A Comprehensive Review
- Review, Var, NA
antiNeop↑, *toxicity↓, TumCCA↑, ROS↑, ER Stress↑, TumAuto↑, Pyro↑, Ferroptosis↑, angioG↓, Imm↝, eff↑, ChemoSen↑, MPT↑, MMP↓, mtDam↑, Cyt‑c↑, Bax:Bcl2↑, Fas↑, DR4↑, DR5↑, JNK↑, ERK↑, CHOP/DDIT3↑, ER Stress↑, UPR↑, Ca+2↑, PI3K↓, Akt↓, mTOR↓, AMPK↑, *Ferroptosis↓, *antiOx↑, *NRF2↑, *GPx4↑, *ROS↓, *MDA↓, *i-Iron↓, *xCT/SLC7A11↑, VEGF↓, Wnt↓, β-catenin/ZEB1↓, EMT↓, STAT3↓, M2 MC↓, MCP1/CCL2↓, MMP9↓, MMP2↓, TIMP2↓, ChemoSen↑, PKM2↑, Glycolysis↓, CSCs↓, SOX4↓, OCT4↓, CD44↓, Nanog↓, MDR1↓, *GutMicro↑,
2351- lamb,    Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
proCasp3↓, proPARP↓, LDHA↓, Glycolysis↓, HK2↓, PKM2↓, lactateProd↓, p‑STAT3↓, cycD1/CCND1↓, cMyc↓, β-catenin/ZEB1↓, p‑GSK‐3β↓, ROS↑, eff↓, Warburg↓,
8151- lamb,    Suppression of STAT3 Phosphorylation and RelA/p65 Acetylation Mediated by MicroRNA134 Plays a Pivotal Role in the Apoptotic Effect of Lambertianic Acid
- in-vitro, BC, MCF7 - in-vitro, Pca, DU145 - in-vitro, Pca, PC3 - in-vitro, BC, MDA-MB-231
TumCCA↑, cl‑PARP↑, p‑STAT3↓, NF-kB↓, XIAP?, survivin↓, Bcl-2↓, Bcl-xL↓, VEGF↓, COX2/PTGS2↓, cMyc↓, IL6↓, TNF-α↓, ac‑p65↑, Obesity↓, miR-134↑,
8156- lamb,    A review on chemistry, source and therapeutic potential of lambertianic acid
- Review, Var, NA
*Obesity↓, *AntiCan↑, *AMPK↑, *β-HEX↓, NA↑, TumCCA↑, AMPK↑, ACC↑, p‑Akt↓, FOXM1↓, CycB/CCNB1↓, XIAP↓, Bcl-2↓, p‑STAT3↓, p‑NF-kB↓, Bcl-xL↓, survivin↓, VEGF↓, COX2/PTGS2↓, cMyc↓, IL6↓, TNF-α↓, ROS↑, STK11/LKB1↑, cl‑Casp3↑, cl‑PARP↑, eff↑, AR↓, TumCP↓, p‑P53↓, P21↓, p27/CDKN1B↓, cycD1/CCND1↓, CDK4↓, PSA↓, STAT3↓, ac‑p65↓, *antiAll↑,
8176- Las,    In Vitro and In Vivo Anti-Cancer Activity of Lasiokaurin in a Triple-Negative Breast Cancer Model
- vitro+vivo, BC, NA
TumCCA↑, Apoptosis↑, DNAdam↑, TumMeta↓, PI3K↓, Akt↓, mTOR↓, STAT3↓, TumVol↓, toxicity↓,
8179- Las,    Lasiokaurin suppresses hepatocellular carcinoma proliferation and induces apoptosis via the JAK2/STAT3 pathway
- in-vitro, HCC, NA
Apoptosis↑, TumCCA↑, TumCG↓, JAK2↓, STAT3↓,
8209- LCA,    Licochalcone A Exerts Anti-Cancer Activity by Inhibiting STAT3 in SKOV3 Human Ovarian Cancer Cells
- in-vitro, Ovarian, SKOV3
tumCV↓, TumCCA↑, ROS↑, MMP↓, Apoptosis↑, cl‑Casp↑, Cyt‑c↑, STAT3↓, TumCP↓, Dose↝, p‑STAT3↓,
8222- LCA,    Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF-κB Signaling Pathways
- in-vitro, CCA, KKU-100 - in-vitro, CCA, KKU-213 - in-vitro, CCA, KKU-214 - in-vitro, CCA, KKU-156 - in-vitro, 0-Reserved, KKU-452
TumCP?, TumCD?, ROS↑, NRF2↓, BAX↑, Cyt‑c↑, TumCMig↓, TumCCA↑, NF-kB↓, STAT3↓, cycD1/CCND1↓, VEGF↓, ICAM-1↓,
8236- LE,    Licorice (Glycyrrhiza glabra L.)-Derived Phytochemicals Target Multiple Signaling Pathways to Confer Oncopreventive and Oncotherapeutic Effects
- Review, Var, NA
Bcl-2↓, CDK2↓, PI3K↓, cJun↓, mTOR↓, NF-kB↓, VEGF↓, MMP3↓, toxicity↓, Dose↑, chemoP↑, *antiOx↑, *Inflam↓, Dose↝, *COX2/PTGS2↓, *iNOS↓, *IL6↓, *IL10↓, *PGE2↓, *IκB?, *NRF2↑, *HO-1↑, *lipid-P↓, *ROS↓, *Catalase↑, *GPx↑, *SOD↑, Apoptosis↑, ROS↑, TumCP↓, TumCCA↑, cycE/CCNE↓, cycD1/CCND1↓, p‑GSK‐3β↓, PI3K↓, MKK4↓, MKK7↓, HSP90↓, LC3‑Ⅱ/LC3‑Ⅰ↑, Beclin-1/ATG6↑, p62↓, p‑Akt↓, cl‑Casp9↑, cl‑Casp7↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Cyt‑c↑, P53↑, STAT3↓, E-cadherin↑, Vim↓, N-cadherin↓, CD31/PECAM-1↓, Hif1a↓, iNOS↓, DNAdam↑, MMP↓, BIM↑, APAF1↑, PCNA↓, toxicity↝, eff↑,
8131- LF,    Molecular mechanism of inhibitory effects of bovine lactoferrin on the growth of oral squamous cell carcinoma
- in-vitro, OS, HSC2 - in-vitro, OS, HSC3 - in-vitro, OS, HSC4 - in-vitro, Nor, RT7
P53↑, Akt↓, SOCS-3↑, mTOR↓, JAK↓, STAT3↓, selectivity↑, TumCP↓, Iron↓, TumCCA↑,
8196- LGE,    Lemongrass essential oil and citral inhibit Src/Stat3 activity and suppress the proliferation/survival of small-cell lung cancer cells, alone or in combination with chemotherapeutic agents
- in-vitro, Lung, NA
Bcl-xL↓, Mcl-1↓, TumCP↓, STAT3↑, TumCP?,
1025- LT,  Api,    Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer
- in-vivo, Lung, NA
TumCG↓, Apoptosis↑, PD-L1↓, p‑STAT3↓,
2925- LT,    Luteolin Induces Carcinoma Cell Apoptosis through Binding Hsp90 to Suppress Constitutive Activation of STAT3
- in-vitro, Cerv, HeLa - in-vitro, Nor, HEK293 - in-vitro, BC, MCF7
HSP90↓, p‑STAT3↓, Apoptosis↑, selectivity↑,
2924- LT,    Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1
- in-vitro, GC, NA - in-vivo, NA, NA
p‑STAT3↓, STAT3↓, Mcl-1↓, survivin↓, Bcl-xL↓, HSP90↓,
2921- LT,    Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies
- Review, Nor, NA
*hepatoP↑, *AMPK↑, *SIRT1↑, *ROS↓, STAT3↓, TNF-α↓, NF-kB↓, *IL2↓, *IFN-γ↓, *GSH↑, *SREBP1/SREBF1↓, *ZO-1↑, *TLR4↓, BAX↑, Bcl-2↓, XIAP↓, Fas↑, Casp8↑, Beclin-1/ATG6↑, *TXNIP↓, *Casp1↓, *IL1β↓, *IL18↓, *NLRP3↓, *MDA↓, *SOD↑, *NRF2↑, *ER Stress↓, *ALAT↓, *AST↓, *iNOS↓, *IL6↓, *HO-1↑, *NQO1↑, *PPARα↑, *ATF4↓, *CHOP/DDIT3↓, *Inflam↓, *antiOx↑, *GutMicro↑,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP/DDIT3↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1/ATG6↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,
3268- Lyco,    Lycopene as a Natural Antioxidant Used to Prevent Human Health Disorders
- Review, AD, NA
*BioAv↓, *AntiCan↑, *ROCK1↓, *Ki-67↓, *ICAM-1↓, *cardioP↑, *antiOx↑, *NQO1↑, *HO-1↑, *TNF-α↓, *IL22↓, *NRF2↑, *NF-kB↓, *MDA↓, *Catalase↑, *SOD↑, *GSH↑, *cognitive↑, *tau↓, *hepatoP↑, *MMP2↑, *AST↓, *ALAT↓, *P450↑, *DNAdam↓, *ROS↓, *neuroP↑, *memory↑, *Ca+2↓, *Dose↝, *Dose↑, *Dose↝, *toxicity∅, PGE2↓, CDK2↓, CDK4↓, STAT3↓, NOX↓, NOX4↓, ROS↓, *SREBP1/SREBF1↓, *FASN↓, *ACC↓,
3264- Lyco,    Pharmacological potentials of lycopene against aging and aging‐related disorders: A review
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
*antiOx↑, *ROS↓, *SOD↑, *Catalase↑, *GSH↑, *GSTs↑, *MDA↓, *lipid-P↓, *NRF2↑, *HO-1↑, *iNOS↓, *NO↓, *TAC↑, *NOX4↓, *Inflam↓, *IL1↓, *IL6↓, *IL8↓, *IL1β↓, *TNF-α↓, *TLR2↓, *TLR4↓, *VCAM-1↓, *ICAM-1↓, *STAT3↓, *NF-kB↓, *ERK↓, *BP↓, ROS↓, PGE2↓, cardioP↑, *neuroP↑, *creat↓, *RenoP↑, *CRM↑,
3277- Lyco,    Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent
- Review, Var, NA
antiOx↑, TumCP↓, Apoptosis↑, TumMeta↑, ChemoSen↑, BioAv↓, Dose↝, BioAv↓, BioAv↑, SOD↑, Catalase↑, GPx↑, IL2↑, IL4↑, IL1↑, TNF-α↑, GSH↑, GPx↑, GSTA1↑, GSR↑, PPARγ↑, Casp3↑, NF-kB↓, COX2/PTGS2↓, Bcl-2↑, BAX↓, P53↓, CHK1↓, Chk2↓, γH2AX↓, DNAdam↓, ROS↓, P21↑, PCNA↓, β-catenin/ZEB1↓, PGE2↓, ERK↓, cMyc↓, cycE/CCNE↓, JAK1↓, STAT3↓, SIRT1↑, cl‑PARP↑, cycD1/CCND1↓, TNF-α↓, IL6↓, p65↓, MMP2↓, MMP9↓, Wnt↓,
1708- Lyco,    The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies
- Review, Var, NA
OS↑, ChemoSen↑, QoL↑, PSA∅, eff↑, AntiCan↑, AntiCan↑, angioG↓, VEGF↓, Hif1a↓, SOD↑, Catalase↑, GPx↑, GSH↑, GPx↑, GR↑, MDA↓, NRF2↑, HO-1↑, COX2/PTGS2↓, PGE2↓, NF-kB↓, IL4↑, IL10↑, IL6↓, TNF-α↓, PPARγ↑, TumCCA↑, FOXO3↓, Casp3↑, IGF-1↓, p27/CDKN1B↑, STAT3↓, CDK2↓, CDK4↓, P21↑, PCNA↓, MMP7↓, MMP9↓,
4795- Lyco,    Updates on the Anticancer Profile of Lycopene and its Probable Mechanism against Breast and Gynecological Cancer
- Review, BC, NA
TumCG↓, TumCCA↑, Apoptosis↑, P53↝, BAX↝, cycD1/CCND1↓, ERK↓, Akt↓, STAT3↓, NRF2↝, NF-kB↓, ITGB1↓, ITGA5↓, FAK↓, MMP9↓, EMT↓,
4793- Lyco,    Lycopene treatment inhibits activation of Jak1/Stat3 and Wnt/β-catenin signaling and attenuates hyperproliferation in gastric epithelial cells
- in-vitro, GC, AGS
antiOx↑, AntiCan↑, ROS↓, JAK1↓, STAT3↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, cycE/CCNE↓, TumCP↓, Risk↓,
1197- MAG,    Magnolol as STAT3 inhibitor for treating multiple sclerosis by restricting Th17 cells
- in-vivo, MS, NA
Weight↑, Th17↓, STAT3↓,
1782- MEL,    Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, eff↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX/CA9↑, P21↑, p27/CDKN1B↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2/PTGS2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
2379- MET,    Down‐regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer
- in-vitro, Bladder, T24/HTB-9 - in-vitro, BC, UMUC3
PKM2↓, p‑STAT3↓, TumCG↓, eff↑, chemoP↑, AMPK↑,
3483- MF,    Pulsed Electromagnetic Fields Protect Against Brain Ischemia by Modulating the Astrocytic Cholinergic Anti-inflammatory Pathway
- NA, Stroke, NA
*Inflam↓, *STAT3↓, *p‑STAT3↓,
533- MF,    Effects of extremely low-frequency magnetic fields on human MDA-MB-231 breast cancer cells: proteomic characterization
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
TumCD↑, necrosis↑, mt-ROS↑, other↑, *STAT3↓, STAT3↑,
1203- MSM,    Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b Pathways
- vitro+vivo, BC, MDA-MB-231
tumCV↓, STAT3↓, STAT5↓, IGF-1↓, Hif1a↓, VEGF↓, Brk/PTK6↓, IGF-1R↓,
1170- MushCha,    Chaga mushroom extract suppresses oral cancer cell growth via inhibition of energy metabolism
- in-vitro, Oral, HSC4
tumCV↓, TumCP↓, TumCCA↑, STAT3↓, Glycolysis↓, MMP↓, TumAuto↑, p38↑, NF-kB↑,
930- MushShi,    Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation
- in-vitro, Ovarian, NA
p‑STAT3↓, PTPN6↑, cycD1/CCND1↓, Bcl-2↓, Mcl-1↓, survivin↓, VEGF↓,
1807- NarG,    A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies
- Review, NA, NA
AntiTum↑, TumCP↓, tumCV↓, TumCCA↑, Mcl-1↓, RAS↓, e-Raf↓, VEGF↓, AntiAg↑, MMP2↓, MMP9↓, TIMP2↑, TIMP1↑, p38↓, Wnt↓, β-catenin/ZEB1↑, Casp↑, P53↑, BAX↑, COX2/PTGS2↓, GLO-I↓, CYP1A1↑, lipid-P↓, p‑Akt↓, p‑mTOR↓, VCAM-1↓, P-gp/ABCB1↓, survivin↓, Bcl-2↓, ROS↑, ROS↑, MAPK↑, STAT3↓, chemoP↑,
5253- NCL,    Niclosamide: Beyond an antihelminthic drug
- Review, Var, NA
TumCP↓, Apoptosis↑, EMT↓, β-catenin/ZEB1↓, TumCG↓, toxicity↓, Wnt↓, LRP6↓, eff↑, DR5↑, mTORC1↓, pH↓, CSCs↓, IL6↓, JAK1↓, STAT3↓, ChemoSen↑, TumCG↓, tumCV↓, NOTCH↓, NF-kB↓, EGFR↓, ROS↑, RadioS↑, cFos↓, cJun↓, E2Fs↓, cMyc↓, Half-Life↓, BioAv↝,

Showing Research Papers: 251 to 300 of 394
Prev Page 6 of 8 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 394

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

miR-134↑, 1,   NA↑, 2,   TCF7/TCF1↓, 1,   TFE3↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Catalase↓, 2,   Catalase↑, 2,   CYP1A1↓, 1,   CYP1A1↑, 1,   Ferroptosis↑, 1,   GPx↓, 1,   GPx↑, 4,   GSH↓, 2,   GSH↑, 2,   GSR↓, 1,   GSR↑, 1,   GSTA1↑, 1,   GSTs↓, 1,   HO-1↓, 1,   HO-1↑, 1,   Iron↓, 1,   lipid-P↓, 1,   MDA↓, 1,   NOX4↓, 1,   NQO1↓, 1,   NRF2↓, 5,   NRF2↑, 1,   NRF2↝, 1,   ROS↓, 8,   ROS↑, 16,   mt-ROS↑, 1,   SOD↓, 2,   SOD↑, 2,   SOD2↓, 1,   Trx↓, 1,   Trx1↑, 1,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 2,   CDC2↓, 1,   MEK↓, 1,   mitResp↓, 1,   MKK4↓, 1,   MKK7↓, 1,   MMP↓, 10,   MPT↑, 1,   mtDam↑, 2,   OCR↓, 1,   e-Raf↓, 1,   XIAP?, 1,   XIAP↓, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↑, 1,   AMPK↑, 3,   CAIX/CA9↑, 1,   cMyc↓, 6,   GLO-I↓, 1,   GlucoseCon↑, 1,   Glycolysis↓, 4,   HK2↓, 2,   lactateProd↓, 1,   LDHA↓, 1,   PFK1↓, 1,   PKM2↓, 3,   PKM2↑, 1,   PPARγ↑, 2,   Pyruv↓, 1,   SIRT1↓, 1,   SIRT1↑, 1,   STK11/LKB1↑, 1,   TS↓, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 10,   p‑Akt↓, 6,   APAF1↑, 2,   Apoptosis↑, 16,   BAX↓, 1,   BAX↑, 9,   BAX↝, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 11,   Bcl-2↑, 1,   Bcl-xL↓, 4,   BIM↑, 1,   Casp↑, 2,   cl‑Casp↑, 1,   Casp1↓, 1,   Casp3↑, 8,   cl‑Casp3↑, 3,   proCasp3↓, 1,   Casp7↑, 1,   cl‑Casp7↑, 1,   Casp8↑, 3,   Casp9↑, 5,   cl‑Casp9↑, 1,   proCasp9↓, 1,   Chk2↓, 1,   Cyt‑c↑, 7,   DR4↑, 2,   DR5↑, 5,   Fas↑, 3,   FasL↑, 1,   Ferroptosis↑, 1,   HGF/c-Met↓, 1,   hTERT/TERT↓, 2,   iNOS↓, 1,   JNK↑, 3,   p‑JNK↑, 2,   MAPK↓, 2,   MAPK↑, 3,   Mcl-1↓, 4,   MCT1↓, 1,   MDM2↓, 1,   p‑MDM2↓, 1,   necrosis↑, 1,   p27/CDKN1B↓, 1,   p27/CDKN1B↑, 3,   p38↓, 1,   p38↑, 1,   p‑p38↑, 2,   Pyro↑, 1,   survivin↓, 5,   TumCD?, 1,   TumCD↑, 2,   YAP/TEAD↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 2,   H3↓, 1,   H4↓, 1,   miR-21↓, 1,   other↑, 1,   tumCV↓, 6,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 3,   p‑eIF2α↑, 1,   ER Stress↑, 2,   HSP27↓, 1,   HSP90↓, 3,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1/ATG6↑, 4,   BNIP3↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3II↑, 2,   MitoP↓, 1,   p62↓, 2,   TumAuto↑, 3,  

DNA Damage & Repair(tgid=10) ⓘ

CHK1↓, 1,   DNAdam↓, 1,   DNAdam↑, 2,   DNArepair↑, 1,   P53↓, 1,   P53↑, 6,   P53↝, 1,   p‑P53↓, 1,   PARP↓, 1,   PARP↑, 2,   cl‑PARP↑, 6,   proPARP↓, 1,   PCNA↓, 4,   γH2AX↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK2↓, 6,   CDK4↓, 5,   cycA1/CCNA1↓, 1,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 5,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 9,   cycE/CCNE↓, 3,   E2Fs↓, 1,   P21↓, 1,   P21↑, 3,   TumCCA↓, 1,   TumCCA↑, 21,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD34↓, 1,   CD44↓, 1,   cFos↓, 1,   cFos↑, 1,   CSCs↓, 5,   CSCsMark↓, 1,   EMT↓, 10,   ERK↓, 4,   ERK↑, 2,   p‑ERK↓, 1,   FOXM1↓, 1,   FOXO3↓, 2,   p‑GSK‐3β↓, 3,   HDAC↓, 1,   IGF-1↓, 2,   IGF-1R↓, 2,   LRP6↓, 1,   mTOR↓, 9,   p‑mTOR↓, 2,   mTORC1↓, 1,   Nanog↓, 1,   NOTCH↓, 2,   NOTCH1↓, 1,   OCT4↓, 1,   PI3K↓, 8,   p‑PI3K↓, 1,   PTEN↓, 1,   PTEN↑, 3,   PTPN6↑, 1,   RAS↓, 1,   p‑Src↓, 1,   STAT3↓, 34,   STAT3↑, 3,   STAT3↝, 1,   p‑STAT3↓, 12,   STAT5↓, 1,   p‑STAT5↓, 1,   p‑STAT6↓, 1,   TK1↓, 1,   TumCG↓, 7,   TumCG↑, 1,   Wnt↓, 7,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   AP-1↓, 1,   AXL↓, 1,   Brk/PTK6↓, 1,   Ca+2↑, 1,   CD31/PECAM-1↓, 1,   Cdc42↓, 1,   CEA↓, 1,   Chl↑, 1,   CLDN1↓, 1,   CLDN2↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 4,   FAK↓, 3,   ITGA5↓, 1,   ITGB1↓, 2,   Ki-67↓, 1,   LEF1↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP13↓, 1,   MMP2↓, 7,   MMP3↓, 1,   MMP7↓, 1,   MMP9↓, 7,   N-cadherin↓, 3,   PAK1↓, 1,   Rac1↓, 1,   Rho↓, 1,   Snail↓, 3,   SOX4↓, 1,   TIMP1↑, 1,   TIMP2↓, 1,   TIMP2↑, 1,   Treg lymp↓, 1,   TumCI↓, 2,   TumCMig↓, 3,   TumCP?, 2,   TumCP↓, 17,   TumMeta↓, 2,   TumMeta↑, 2,   Twist↓, 1,   Tyro3↓, 1,   VCAM-1↓, 1,   Vim↓, 4,   Vim↑, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 7,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 5,   EGFR↓, 1,   EGFR↑, 1,   p‑EGFR↓, 1,   HIF-1↓, 1,   Hif1a↓, 5,   NO↓, 1,   VEGF↓, 14,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,   GLUT1↑, 1,   GLUT3↑, 1,   GLUT4↓, 1,   P-gp/ABCB1↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↓, 1,   CD4+↑, 1,   COX2/PTGS2↓, 6,   FOXP3↓, 1,   ICAM-1↓, 2,   IKKα↓, 1,   IL1↓, 1,   IL1↑, 1,   IL10↑, 1,   IL2↑, 2,   IL4↑, 2,   IL6↓, 8,   IL8↓, 1,   Imm↝, 1,   Inflam↓, 2,   JAK↓, 2,   JAK1↓, 3,   JAK1↑, 1,   JAK2↓, 2,   M2 MC↓, 1,   MCP1/CCL2↓, 1,   NF-kB↓, 14,   NF-kB↑, 1,   p‑NF-kB↓, 1,   NK cell↑, 1,   p65↓, 1,   p‑p65↓, 1,   ac‑p65↓, 1,   ac‑p65↑, 1,   PD-1↓, 1,   PD-L1↓, 1,   PGE2↓, 4,   PSA↓, 1,   PSA∅, 1,   SOCS-3↓, 1,   SOCS-3↑, 1,   T-Cell↑, 1,   Th1 response↑, 1,   Th17↓, 1,   TNF-α↓, 7,   TNF-α↑, 2,  

Cellular Microenvironment(tgid=17) ⓘ

NOX↓, 1,   pH↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,   GR↑, 1,   RANKL↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 4,   BioAv↝, 2,   ChemoSen↑, 15,   Dose↓, 1,   Dose↑, 1,   Dose↝, 3,   Dose∅, 1,   eff↓, 3,   eff↑, 9,   Half-Life↓, 1,   MDR1↓, 2,   RadioS↑, 3,   selectivity↑, 6,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 2,   CEA↓, 1,   EGFR↓, 1,   EGFR↑, 1,   p‑EGFR↓, 1,   FOXM1↓, 1,   GutMicro↑, 1,   hTERT/TERT↓, 2,   IL6↓, 8,   Ki-67↓, 1,   NSE↓, 1,   PD-L1↓, 1,   PSA↓, 1,   PSA∅, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 4,   antiNeop↑, 1,   AntiTum↑, 2,   cachexia↓, 1,   cardioP↑, 2,   chemoP↑, 5,   ChemoSideEff↓, 1,   Obesity↓, 1,   OS↑, 2,   QoL↑, 1,   radioP↑, 1,   Risk↓, 2,   toxicity↓, 3,   toxicity↝, 1,   TumVol↓, 1,   Weight↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 369

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

antiAll↑, 1,   AntiBio↑, 1,   AntiP↑, 1,   autophagy↓, 1,   DUOX1↓, 1,   NOX2↓, 1,   β-HEX↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 7,   Catalase↑, 6,   Ferroptosis↓, 1,   GPx↑, 3,   GPx4↑, 1,   GSH↑, 5,   GSR↑, 1,   GSTs↑, 3,   HO-1↑, 5,   i-Iron↓, 1,   lipid-P↓, 4,   MDA↓, 4,   NOX4↓, 2,   NQO1↑, 3,   NRF2↑, 8,   ROS↓, 10,   SOD↑, 7,   SOD1↑, 1,   SOD2↑, 1,   TAC↑, 1,   xCT/SLC7A11↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↑, 1,   mtDam↓, 1,   PINK1↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↓, 1,   ALAT↓, 2,   AMPK↑, 2,   ATG7↓, 1,   CRM↑, 1,   FASN↓, 1,   PPARα↑, 1,   SIRT1↑, 1,   SREBP1/SREBF1↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↝, 1,   Apoptosis↓, 1,   Casp1↓, 1,   Casp3↓, 1,   Ferroptosis↓, 1,   iNOS↓, 3,   p‑JNK↓, 1,   MAPK↝, 1,   p‑p38↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   ER Stress↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

BNIP3↓, 1,   LC3B↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   STAT3↓, 4,   STAT3↝, 1,   p‑STAT3↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↓, 1,   Ki-67↓, 1,   MMP2↑, 1,   ROCK1↓, 1,   TGF-β↑, 1,   TXNIP↓, 1,   VCAM-1↓, 1,   ZO-1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

ATF4↓, 1,   NO↓, 2,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   ICAM-1↓, 2,   IFN-γ↓, 1,   IL1↓, 1,   IL10↓, 1,   IL10↑, 1,   IL18↓, 1,   IL1β↓, 4,   IL2↓, 1,   IL22↓, 1,   IL6↓, 4,   IL8↓, 1,   Inflam↓, 6,   IκB?, 1,   JAK↓, 1,   NF-kB↓, 2,   PGE2↓, 1,   TLR2↓, 1,   TLR4↓, 2,   TNF-α↓, 4,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 1,   Dose↑, 1,   Dose↝, 3,   eff↑, 1,   Half-Life↝, 1,   P450↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 2,   BP↓, 1,   creat↓, 1,   GutMicro↑, 2,   IL6↓, 4,   Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   AntiDiabetic↑, 1,   AntiTum↓, 1,   cardioP↑, 3,   cognitive↑, 1,   hepatoP↑, 2,   memory↑, 1,   neuroP↑, 4,   Obesity↓, 1,   RenoP↑, 1,   toxicity↓, 1,   toxicity∅, 1,  
Total Targets: 119

Scientific Paper Hit Count for: STAT3, Signal transducer and activator of transcription 3
26 Curcumin
15 Thymoquinone
13 Cucurbitacin
13 Quercetin
12 Apigenin (mainly Parsley)
10 Resveratrol
9 EGCG (Epigallocatechin Gallate)
9 Baicalein
9 Capsaicin
9 Chrysin
9 Garcinol
9 Honokiol
8 Ashwagandha(Withaferin A)
8 Betulinic acid
8 Emodin
8 Ginkgetin
8 Silymarin (Milk Thistle) silibinin
7 Luteolin
6 Berberine
6 brusatol
6 Kaempferol
6 Lycopene
5 Artemisinin
5 Beta-Caryophyllene
5 Caffeic acid
5 Pterostilbene
4 Cisplatin
4 Radiotherapy/Radiation
4 Berbamine
4 Sorafenib (brand name Nexavar)
4 Carnosic acid
4 Celastrol
4 Cynaropicrin
4 Ellagic acid
4 Fisetin
4 Formononetin
4 Ginger/6-Shogaol/Gingerol
4 HydroxyTyrosol
4 Isoliquiritigenin
4 Ivermectin
4 Niclosamide (Niclocide)
4 Piperine
4 Piperlongumine
3 Gemcitabine (Gemzar)
3 Chemotherapy
3 Boswellia (frankincense)
3 Propolis -bee glue
3 Magnetic Fields
3 chaetocin
3 Dandelion Root
3 Gambogic Acid
3 Sulforaphane (mainly Broccoli)
3 isoorientin
3 lambertianic acid
3 Nimbolide
3 Oleocanthal
3 Phenethyl isothiocyanate
3 Rosmarinic acid
3 Shikonin
3 Ursolic acid
2 Andrographis
2 Ascorbyl Palmitate
2 Melatonin
2 Arctigenin
2 Baicalin
2 Brucea javanica
2 borneol
2 Boron
2 Centella asiatica / Gotu kola → asiaticoside
2 Cinnamon
2 immunotherapy
2 Fucoidan
2 Gallic acid
2 Genistein (soy isoflavone)
2 Geraniol
2 Indole-3-carbinol
2 Juglone
2 Lasiodin
2 Licochalcone A
2 Metformin
2 Vitamin C (Ascorbic Acid)
2 Sanguinarine
2 Vitamin K2
1 Allicin (mainly Garlic)
1 Alpha-Lipoic-Acid
1 DTS(dibenzyl trisulphide) from Anamu
1 Anethole/trans-Anethole
1 Astaxanthin
1 Biochanin A
1 Atorvastatin
1 Bufalin/Huachansu
1 Caffeic Acid Phenethyl Ester (CAPE)
1 Carvacrol
1 Trastuzumab
1 Hydroxycinnamic-acid
1 Crocetin
1 Carvone
1 Oxygen, Hyperbaric
1 methylseleninic acid
1 CUSP9
1 Deguelin
1 D-limonene
1 Tetrahydroxystilbene glucoside
1 Ferulic acid
1 Paclitaxel/Taxol
1 Ginkgolic acids
1 Ginseng
1 Hydrogen Gas
1 epipolythiodioxopiperazine / epipolythiopiperazine-2,5-dione
1 Hyperoside
1 Isobavachalcone
1 Inositol
1 isoflavones
1 isoquercitrin
1 Licorice
1 Lactoferrin/Talactoferrin
1 Lemongrass Extract/Citral
1 Magnolol
1 Methylsulfonylmethane
1 Mushroom Chaga
1 Mushroom Shiitake, AHCC
1 Naringin
1 Oleuropein
1 Orlistat
1 Plumbagin
1 VitK3,menadione
1 Parthenolide
1 Rutin
1 buckwheat sprouts
1 salinomycin
1 Urolithin
1 Usnic acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:373  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page